Amgen Canada Update Regarding COVID-19
Each day brings new developments and uncertainty about COVID-19. As the situation continues to evolve, Amgen is committed to doing everything we can to keep our staff, and their families safe, and to reduce the number of people exposed to the virus in our communities.
Our commitment to patients is also unwavering. Amgen continues to provide an uninterrupted supply of medicines for patients around the world. Based on inventory levels, we do not anticipate a shortage of our medicines due to COVID-19 at this time.
With the safety of our team, partners and patients in mind, since Monday, March 16, all Amgen Canada staff who were able to work from home have been doing so until further notice, out of an abundance of caution. Staff members including field staff have moved to a virtual interaction model.
In addition, we have made the decision to:
- Suspend all in-person meetings and interactions with the healthcare community and professionals in Canada
- Suspend international business travel and limit domestic travel within Canada
- Suspend attendance at medical congresses, conferences and other large events
Free online learning programs supported by the Amgen Foundation are available to help students continue their science education during school closures, including LabXchange and Khan Academy’s online learning website.
Patients on Amgen medicines who have questions or concerns about their treatment plan should consult with their doctors. If you have additional questions or concerns, contact us at +1-866-502-6436. For other inquiries, please visit the Contact Us section.
We thank you for your continued cooperation and patience during this time.